Vident Advisory’s Dr. Reddy's Laboratories RDY Stock Holding History

Vident Advisory’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.01M	Buy	217,581 +8,834	+4%	+$123K	0.03%	500
2025 Q4	$2.93M	Buy	208,747 +15,686	+8%	+$220K	0.03%	459
2025 Q3	$2.7M	Buy	193,061 +3,792	+2%	+$54.6K	0.03%	471
2025 Q2	$2.84M	Buy	189,269 +29,242	+18%	+$418K	0.03%	409
2025 Q1	$2.11M	Buy	160,027 +8,696	+6%	+$120K	0.03%	468
2024 Q4	$2.39M	Buy	151,331 +32,266	+27%	+$485K	0.04%	374
2024 Q3	$1.89M	Buy	119,065 +310	+0.3%	+$4.99K	0.05%	405
2024 Q2	$1.81M	Buy	118,755 +4,050	+4%	+$58K	0.05%	405
2024 Q1	$1.68M	Buy	114,705 +4,090	+4%	+$59.7K	0.04%	420
2023 Q4	$1.54M	Buy	110,615 +14,810	+15%	+$198K	0.04%	446
2023 Q3	$1.28M	Buy	+95,805	New	+$1.3M	0.04%	442

Other funds holding RDY

Robeco Institutional Asset Management Rotterdam, Netherlands $70.2B AUM 29.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

Aikya Investment Management London, United Kingdom $345M AUM 10.59% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Vident Advisory's RDY Position: Q1 2026 in Review

Vident Advisory increased its Dr. Reddy's Laboratories (RDY) stake by 4.2% in Q1 2026, buying an estimated $123K and bringing the position to 217,581 shares worth $3.01M. The position accounts for 0.03% of the portfolio, ranked #500.

Vident Advisory first reported a position in RDY in Q3 2023 and has held it in 11 quarters since. 247 funds tracked by Wall St. Rank hold RDY as of Q1 2026.

Vident Advisory held 217,581 shares of Dr. Reddy's Laboratories worth $3.01M as of Q1 2026.
Vident Advisory bought 8,834 Dr. Reddy's Laboratories shares in Q1 2026, an estimated $123K.
Dr. Reddy's Laboratories made up 0.03% of Vident Advisory's portfolio in Q1 2026, its #500 holding.
Vident Advisory first reported a position in Dr. Reddy's Laboratories in Q3 2023 and has held it in 11 quarters since.
247 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.